Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refractory DLBCL. Patients received low-dose conditionin...

Descripción completa

Detalles Bibliográficos
Autores principales: Locke, Frederick L., Neelapu, Sattva S., Bartlett, Nancy L., Siddiqi, Tanya, Chavez, Julio C., Hosing, Chitra M., Ghobadi, Armin, Budde, Lihua E., Bot, Adrian, Rossi, John M., Jiang, Yizhou, Xue, Allen X., Elias, Meg, Aycock, Jeff, Wiezorek, Jeff, Go, William Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293/
https://www.ncbi.nlm.nih.gov/pubmed/28129122
http://dx.doi.org/10.1016/j.ymthe.2016.10.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293/
https://www.ncbi.nlm.nih.gov/pubmed/28129122
http://dx.doi.org/10.1016/j.ymthe.2016.10.020

Ejemplares similares